wavelength. These actions are consistent with the ability of flecainide to produce rate-dependent increases in atrial action potential duration in vitro26 and in vivo. 27 It remains uncertain whether these properties are peculiar to flecainide or are common to class Ic compounds. Furthermore, the antiarrhythmic mechanisms of other drugs in atrial fibrillation remain poorly understood and have not been tested in experimental sustained atrial fibrillation. We designed the present work to study (1) the efficacy of representative class Ia, Ic, and III drugs in experimental atrial fibrillation; (2) their rate-dependent actions on atrial effective refractory period and conduction; and (3) the mechanisms whereby they terminate atrial fibrillation.
We studied procainamide as a class Ia drug because intravenous procainamide is often used to terminate acute atrial fibrillation in humans and the drug causes less hypotension than quinidine. We chose the class Ic Nadolol was administered as an initial dose of 0.5 mg/kg IV, followed by 0.25 mg/kg every 2 hours.28
Atrial Fibrillation Model The cervical vagal trunks were isolated and decentralized, and bipolar hook electrodes were inserted via a 21-gauge needle into the middle of each nerve, with the electrode running parallel to vagal fibers for several centimeters. 29 The Teflon insulation was removed from the distal 1 cm of each electrode. Bilateral vagal nerve stimulation was delivered by a DS-9F stimulator (Grass Instruments, Inc, Quincy, Mass) with a pulse width of 0.1 ms and an applied voltage of 5 V. The stimulation frequency was adjusted in each dog to two thirds of the threshold for asystole under control conditions. In the presence of vagal stimulation, a short burst ( *Data shown are for the number of dogs in whom atrial fibrillation could be induced during the maintenance infusion. The denominator for nonsustained atrial fibrillation induction is the number of dogs in whom sustained atrial fibrillation could not be induced, and the numerator is the number of these animals in which nonsustained atrial fibrillation could be induced by bursts of atrial pacing.
§Includes eight dogs studied with the standard protocol, and five dogs in whom vagal stimulation frequency was increased by 80% for atrial fibrillation induction before drug infusion (see Fig 3) . fibrillation induction, and the vagal stimulation frequency was adjusted to produce consistent sinus node slowing. A similar procedure was used to establish vagal stimulation parameters during maintenance drug infusion.
Activation Mapping
Five thin plastic sheets containing 112 bipolar electrodes with 1-mm interpolar and 6-mm interelectrode distances were sewn into position on the atrial epicardial surface (Fig 1) . One sheet was placed under the root of the aorta to cover the anterior aspect of the atrial appendages and Bachman's bundle. Three sheets were sewn to the posterior aspects of the atrial appendages and to the free walls. The parietal pericardium was gently separated, and a fifth plaque was placed between the pulmonary arteries and veins.
Each Sustained atrial fibrillation could be induced in only 3 of 10 dogs (30%) after propafenone (the dogs in whom propafenone failed to terminate atrial fibrillation) and in no dogs after procainamide or high-dose sotalol. After low-dose sotalol, however, sustained atrial fibrillation could be induced in all dogs ( Table 2 ). The prevention of atrial fibrillation induction could not be due to antivagal actions because vagal frequency was readjusted during each maintenance dose to produce the same bradycardic effect as under control conditions (see "Methods").
Neither propafenone nor sotalol showed significant antivagal actions (Fig 2) . Procainamide, on the other hand, significantly reduced the bradycardic effects of vagal stimulation (Fig 2) , consistent with its ability to block ganglionic transmission.38 The termination of atrial fibrillation by procainamide thus could have been due to antivagal actions. To control for antivagal actions, we studied five additional dogs in which vagal stimulation frequency was increased by 80% during atrial fibrillation before procainamide infusion. The adequacy of this adjustment was assessed by comparing the control vagal frequency-response curve to the curve in the presence of procainamide after atrial fibrillation termination (Fig 3) (Fig 4) . Propafenone reversed the rate dependence of atrial effective refractory period so that it increased with decreasing cycle length. Consequently, propafenone increased atrial effective refractory period more at faster rates. Sotalol showed an opposite profile of action, with effects being largest at long cycle lengths (slow rates). Vagal stimulation markedly abbreviated atrial effective refractory period, whereas all three drugs increased atrial effective refractory period.
To appreciate better the rate dependence of drug action, we calculated the drug-induced increase in effective refractory period relative to the corresponding control value at each cycle length in each experiment (Fig 4, bottom) . Effects at a given cycle length that are significantly different from those at a basic cycle length of 400 ms are shown by the asterisks in the lower panels of Fig 4. A similar approach was taken to the analysis of rate-dependent changes in conduction velocity (Fig 5) and wavelength (Fig 6) . The effects of sotalol were dose dependent and increased with increasing cycle length. Propafenone increased effective refractory period most at short cycle lengths, whereas procainamide's actions did not change with cycle length. All drugs increased atrial effective refractory period more in the presence of vagal stimulation (right) than in its absence (left).
Changes in conduction velocity are illustrated in Fig  5. Neither vagal stimulation nor sotalol altered conduction velocity. Sotalol's ability to increase effective refractory period without changing conduction velocity confirms its class III actions in the canine atrium.
Propafenone and procainamide slowed atrial conduction, with their effects exaggerated by decreasing basic cycle length. Drug effects on conduction were not altered by vagal stimulation.
Vagal stimulation strongly reduced the wavelength for reentry (Fig 6) , decreasing the value at a cycle length of 150 ms from a mean of 11.1+0.4 cm to 7.1±0.4 cm (P<.001). Sotalol's effects on wavelength were reduced as cycle length decreased, paralleling its actions on effective refractory period. In the presence of vagal stimulation, large changes in effective refractory period resulted in substantial prolongation of wavelength by propafenone. In the absence of vagal stimulation, propafenone had little effect on wavelength, with a greater tendency to increase wavelength at smaller, compared with larger, cycle lengths (Fig 6, bottom left) . Procainamide increased wavelength in a rate-independent fashion.
During vagal stimulation, propafenone, procainamide, and high-dose sotalol increased wavelength (basic cycle length, 200 ms) from about 8 cm to 12 figure (Figs 4 through 6) is between drug and control values (raw data) at each basic cycle length, whereas the statistical significance at the bottom is for the comparison between percent change produced by a drug at a given basic cycle length and its effects at a basic cycle length of 400 ms.
Drug Effects on Activation During Atrial Fibrillation
All three agents slowed atrial activation during atrial fibrillation. Figure 7 shows the mean cycle length of atrial fibrillation under control conditions and immediately prior to atrial fibrillation termination. The mean atrial fibrillation cycle length was determined, as previously done,25 by counting the number of cycles over a 1-second period. The cycle length of atrial fibrillation was determined for at least 16 electrode sites widely dispersed over the atria, and the average at all sites was taken to represent the atrial fibrillation cycle length. Although all three agents increased the atrial fibrillation cycle length, the atrial fibrillation slowing effect of sotalol was significantly less than that of the other two drugs.
The mechanism of drug termination of atrial fibrillation was further explored on the basis of activation mapping. Consider electrograms J1 through J8. J2 and J3 are initially activated just at the onset of the window. The impulse propagates through J6 and J7, passing close to J5 as shown by the low-amplitude potential at that site. Zones of crowded isochrones representing slow conduction or block are indicated by the stippled lines above and below the J2-J3 zone in panel C. The impulse travels superiorly around this region of functional block to activate I4, J1, and then J5. The latter is activated 52 ms after initial activation at J2, and J2 is reactivated 9 ms later, just before reactivation at J3 (panel B). The activation-reactivation interval at J2 is 61 ms, in the range of atrial effective refractory period during vagal stimulation. Similar reentry cycles occur at F2, N5, and K3-K6. The activation-reactivation intervals in each zone are similar to the mean atrial fibrillation cycle Figure 9 shows the change in activation caused by procainamide immediately before termination of atrial fibrillation in the same dog as Fig 8. Figure 9, Figure 10 shows an example of atrial fibrillation termination by propafenone. Activation begins near Bachman's bundle (sites L2-L4) and proceeds rapidly through both atria toward the atrioventricular ring. A zone of relative refractoriness is present in the posterior left atrium, and activation in this region begins at sites K1 and K2, resulting in rather symmetrical activation in this zone. The mechanism by which the impulse reaches K1 and K2 is unclear, but it may involve conduction from C2 and C3 or H8 via the septum. The next activation (panel B) begins at sites activated early in the preceding cycle (A) adjacent to the zone activated late in cycle A. The posterior left atrium superior to (and including) sites K1 and K2 is activated with a substantial delay, indicating block in the conduction path by which K1 and K2 were previously excited. Because of this delay, the remaining portions of the atria recover excitability and are activated rapidly and symmetrically from the region around K1 and K2. This last activation is illustrated in panel C, in which activation times are referenced to the same time point as in cycle B. As in Fig 9, the drug resulted in a large macroreentry circuit. Block in a critical zone led to recovery of remaining atrial tissue, with consequent rapid, symmetrical activation precluding the possibility of further reentrant cycles. Figures 11 and 12 illustrate the effects of low-and high-dose sotalol, respectively, on atrial activation during atrial fibrillation. Electrogram recordings from eight sites under control conditions are shown in Fig 11, Overall, although the duration of activation-reactivation cycles is slightly larger in the presence of the drug (panels D through F), there is little qualitative change in atrial activation compared with control (panels A through C). Figure 12 shows an example of atrial fibrillation termination by high-dose sotalol. Electrograms from the right atrium near the atrioventricular ring (E1-E8) are shown in panel A and from the right atrial appendage (K3-K8) in panel B. Activation maps from the last four cycles of atrial fibrillation are illustrated in panels C through F. The cycle prior to that illustrated in C showed a single macroreentry circuit in the right atrial appendage. The same circuit is evident in panel C but is now accompanied by a second, figure-of-eight macroreentry circuit adjacent to the atrioventricular ring. During the next cycle, illustrated in panel D, reentry terminates in the right atrial appendage because of block at K3, K4, and K6 but continues in the lower right atrium. This is followed by two more cycles in the latter zone (panels E and F), with reentry terminating by block at sites E3, E4, E7, and E8. In contrast to atrial activation in the presence of low-dose sotalol (Fig 11) , activation in the presence of high-dose sotalol is distinguished by a smaller number of reentry circuits, on which the persistence of atrial fibrillation depends. When reexcitation fails in a critical circuit, atrial fibrillation stops.
The detailed mode of atrial fibrillation termination varied from experiment to experiment for all drugs. However, in each case, the number of circuits immediately prior to termination was one or two, and termination occurred either via failure of reexcitation in a macroreentry circuit (as in Figs 9 and 12 ) or symmetrical spread from a single region (as in Fig 10) . The former mechanism was involved in 6 of 12 terminations mapped for procainamide, 2 of 7 for propafenone, and 4 of 7 for sotalol, whereas variants of the latter mechanism were responsible for the remainder. Discussion We have shown that propafenone, procainamide, and sotalol are all capable of terminating atrial fibrillation and preventing its induction in a dog model of sustained atrial fibrillation. Effective doses of all three agents increase the wavelength at short cycle lengths, slow atrial activation during atrial fibrillation, and increase the size of reentry circuits.
Comparison With Previous Experimental Studies ofAntiarrhythmic Drug Action During Atrial Fibrillation
Rensma and colleagues23 evaluated the effects of antiarrhythmic drugs on atrial arrhythmias induced by premature stimulation in dogs. Their study differs from ours in that they studied the inducibility of nonsustained arrhythmias in conscious dogs, mapping techniques were not used, and the details of drug and dose selection were different. Like them, we found that a cumulative dose of 8 mg/kg sotalol suppresses atrial fibrillation induction. In addition, however, we found that a dose of sotalol (2 mg/kg) slightly larger than the standard clinical intravenous dose of 1.5 mg/kg36'37 has limited ability to terminate atrial fibrillation in our model. This contrasts with the efficacy that we observed for clinical loading doses of procainamide7 and propafenone.9,11 Although Rensma and colleagues did not study procainamide, they found that the class Ia drug quinidine suppressed the induction of atrial arrhythmias. Rensma and colleagues did not report efficacy for propafenone, although Kirchhof and colleagues24 subsequently found another class Ic drug, ORG 7797, to be effective in the same model. Our results resemble those of Rensma and colleagues23 in that interventions that terminate or prevent atrial fibrillation in both models increase the wavelength for atrial reentry. Our results go beyond those of Rensma and colleagues by evaluating use-dependent drug action and by applying activation mapping to correlate electrophysiological effects with changes in activation during atrial fibrillation.
The effects of propafenone in the present experiments resemble those previously noted with flecainide25 and suggest a common mechanism of class lc drug action in atrial fibrillation, with tachycardia-dependent increases in refractoriness counteracting the effects on wavelength of drug-induced conduction slowing. Kirchhof and colleagues also noted use-dependent atrial refractoriness prolongation by ORG 7797.24 The relative importance of changes in action potential duration26,27 and sodium channel blockade in the effective refractory period changes caused by Ic drugs remains to be established.
Implications Regarding Mechanisms of Antiarrhythmic Action Against Atrial Fibrillation
Our results support the role of wavelength in mediating antiarrhythmic action in atrial fibrillation. As previously suggested,23'39'40 increases in wavelength resulted in an increase in the size of functional reentry circuits in our animals. The number of circuits decreased, and the arrhythmia terminated when the remaining circuits failed to sustain themselves. These observations are consistent with the suggested importance of the number of reentrant impulses in sustaining atrial fibrillation.23'4-44 Termination tended to occur in two general ways-failure of reexcitation at a critical point (Figs 9 and 12 ) or a delay in activation allowing for recovery of the remaining portions of the atria (Fig 10) . In the normal atrium, individual reentrant circuits tend to be unstable, so that in the presence of only one or two circuits functional perturbations readily lead to arrhythmia termination.
Although high-dose sotalol caused similar changes in wavelength (Fig 6) and activation patterns compared with the other two drugs, it caused less slowing in the atrial rate during atrial fibrillation (Fig 7) . This is consistent with the smaller increases in atrial effective refractory period produced by sotalol at rapid rates and with the concept that the rate of functional "leading circle" reentry depends on the refractory period,39 not on conduction velocity or wavelength. Both propafenone and procainamide decrease conduction velocity in addition to prolonging refractoriness. Therefore, they need to cause a larger increase in refractoriness than does sotalol to increase the wavelength sufficiently to stop atrial fibrillation. Consequently, class 1 agents produce a greater slowing in atrial activation rate before atrial fibrillation termination. The well-known propensity of class 1 Several studies examined in detail the mechanism of arrhythmia termination. Spinelli and Hoffman50 suggested that failure of the lateral boundaries (ie, shortcircuiting of reentry) or reflection underlie the efficacy of sotalol, whereas class I agents produce block in the reentrant pathway. Schoels and colleagues51 suggested that procainamide terminates atrial flutter by suppressing conduction to the point of block in a slowly conducting portion of the reentry circuit. Class I drugs did not eliminate the excitable gap, as would have been expected had they increased wavelength beyond the pathlength available.
The nature of the arrhythmia that we studied was quite different from that of the atrial flutter models. Instead of a single, stable circuit with an anatomicfunctional basis, cholinergic atrial fibrillation involves multiple unstable reentry circuits in functionally normal hearts. Atrial activation during atrial fibrillation prior to drug administration reflected this mechanism, as previously observed experimentally254344 in keeping with Moe's "multiple wavelet hypothesis."'41 '42 In contrast to their effects in atrial flutter, class I drugs increased the wavelength in the vagotonic dog, and this increase in wavelength contributed to atrial fibrillation termination by reducing the number of co-existent reentry circuits. On the other hand, it is quite possible that the final extinction of individual macroreentry circuits occurred via mechanisms similar to those previously described in atrial flutter models. For example, the small deflections indicated by arrows in Fig 9, (Fig 4) , its effect was reduced by two thirds at a basic cycle length of 200 ms, resulting in small changes in wavelength and limited ability to terminate atrial fibrillation. The small effect of 2 mg/kg sotalol on wavelength at rapid rates, due to reverse use dependence, accounts for the minor effects of low-dose sotalol on activation patterns during atrial fibrillation (Fig 11) .
Limited clinical studies of sotalol in the termination of atrial fibrillation have shown relatively low efficacy,37 with the exception of postoperative atrial fibrillation,21 for which a-blockers appear to be particularly effective. 54 
Study Limitations
Our model has a number of advantages, including the reliability of atrial fibrillation induction, the sustained nature of vagal atrial fibrillation, and the prompt termination of atrial fibrillation when vagal stimulation is stopped. Propafenone and procainamide were effective at doses and concentrations of the same order as those that terminate atrial fibrillation of recent onset in humans.7'9'11 Enhancement of vagal tone may also play an important role in the clinical occurrence of atrial fibrillation.57 Our model fails to reproduce the abnormal electrophysiological substrate58'59 caused by atrial pathology often associated with atrial fibrillation, and may therefore not apply to atrial fibrillation in the setting of structural heart disease. Further observations in experimental atrial fibrillation models involving atrial disease, along with related studies in clinical atrial fibrillation, would be of interest.
The role of vagal tone poses the problem of effects due to antivagal properties. The impact of vagolytic properties was minimized during the assessment of drug effects on effective refractory period, conduction velocity, and atrial fibrillation induction by adjusting vagal stimulation frequency during the maintenance drug infusion to produce the same bradycardic effect as under control conditions. To control for the role of procainamide's vagolytic properties in terminating atrial fibrillation, we increased vagal frequency before procainamide infusion in five dogs, producing a bradycardic action in the presence of drug similar to control conditions. Nonetheless, we cannot completely exclude a contribution to atrial fibrillation termination of vagolytic actions that may have been incompletely controlled by adjusting vagal stimulation frequency.
The effects of all drugs on atrial effective refractory period were greater in the presence of vagal stimulation (Fig 4) . We previously found a similar interaction for flecainide. 25 This interaction between drugs and vagal tone has not, to our knowledge, been reported previously, and its mechanism is unknown. Sodium channel blockade is unlikely to be the sole factor involved because sotalol is devoid of sodium channel-blocking properties at the concentrations studied.60 Recent work indicates that flecainide, propafenone, and disopyramide can inhibit IKAch in guinea pig atrial myocytes.61
The potential importance of this mechanism bears further investigation, particularly because IKACl can be activated in the absence of muscarinic agonists by a membrane-bound nucleoside diphosphate kinase. 62 
Conclusions
We have shown that sotalol, propafenone, and procainamide are effective in terminating sustained atrial fibrillation in an experimental dog model. This is, to our knowledge, the first comparative assessment of antiarrhythmic drug mechanisms and efficacy in an experimental model of sustained atrial fibrillation. The results suggest that increases in wavelength are central in arrhythmia termination. Rate-dependent drug effects on atrial refractoriness can contribute to (in the case of propafenone) or limit (in the case of sotalol) drug efficacy, depending on whether drug actions on effective refractory period are enhanced or reduced by the rapid rates characteristic of atrial fibrillation.
